MedPath

CELLULAR SCIENCES INC

๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:3

Trial Phases

2 Phases

Phase 2:2
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)โ€ข Click on a phase to view related trials

Phase 2
2 (66.7%)
Phase 3
1 (33.3%)

The Effect of N115 on Coughing in IPF Patients

Phase 3
Completed
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Other: Saline Placebo control nasal spray
Drug: 20mM sodium pyruvate nasal spray
First Posted Date
2023-09-14
Last Posted Date
2024-08-07
Lead Sponsor
Cellular Sciences, inc.
Target Recruit Count
50
Registration Number
NCT06037408
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Family First Medical Research Center, Hialeah Gardens, Florida, United States

Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.

Phase 2
Completed
Conditions
Long COVID
Interventions
Drug: sodium pyruvate nasal spray
First Posted Date
2021-05-04
Last Posted Date
2022-03-09
Lead Sponsor
Cellular Sciences, inc.
Target Recruit Count
22
Registration Number
NCT04871815
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Missouri State University, Springfield, Missouri, United States

Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection

Phase 2
Completed
Conditions
COVID-19
Interventions
First Posted Date
2021-04-01
Last Posted Date
2022-11-02
Lead Sponsor
Cellular Sciences, inc.
Target Recruit Count
30
Registration Number
NCT04824365
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Family First Medical Research Center, Virginia Gardens, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

Missouri State University, Springfield, Missouri, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

ยฉ 2025 MedPath, Inc. All rights reserved.